Table 3 Baseline descriptive statistics
|  | Control (N = 36) | Intervention (N = 33) | Total (N = 69) |
|---|---|---|---|
Gender | |||
 Female | 22 (61.1%) | 25 (75.8%) | 47 (68.1%) |
 Male | 14 (38.9%) | 8 (24.2%) | 22 (31.9%) |
Age | |||
 Median (Q1, Q3) | 82.5 (77.5, 88.0) | 86.0 (83.0, 88.0) | 85.0 (79.0, 88.0) |
FAST | |||
 Missing | 1 | 1 | 2 |
 4 | 1 (2.9%) | 2 (6.2%) | 3 (4.5%) |
 5 | 1 (2.9%) | 2 (6.2%) | 3 (4.5%) |
 6 | 24 (68.6%) | 25 (78.1%) | 49 (73.1%) |
 7 | 9 (25.7%) | 3 (9.4%) | 12 (17.9%) |
Charlson | |||
 Median (Q1, Q3) | 1.0 (1.0, 2.0) | 2.0 (1.0, 2.0) | 1.0 (1.0, 2.0) |
MMSE | |||
 Missing | 6 | 3 | 9 |
 Median (Q1, Q3) | 3.0 (1.0, 6.8) | 6.0 (2.0, 10.0) | 4.0 (1.0, 9.2) |
No. of psychotropic drugs | |||
 Mean (range) | 2.91 (1–6) | 2.78 (0–5) | 2.85 (0–6) |
SDI | |||
 Median (Q1, Q3) | 3.0 (0.0, 18.0) | 3.0 (0.0, 12.5) | 3.0 (0.0, 17.5) |
WASO | |||
 Median (Q1, Q3) | 73.9 (34.8, 106.6) | 56.5 (32.9, 85.2) | 62.7 (32.9, 95.0) |